OptimizeRx Corporation

NasdaqCM:OPRX Stock Report

Market Cap: US$90.4m

OptimizeRx Management

Management criteria checks 2/4

OptimizeRx's CEO is Will Febbo, appointed in Feb 2016, has a tenure of 8.83 years. total yearly compensation is $2.79M, comprised of 16.1% salary and 83.9% bonuses, including company stock and options. directly owns 2.86% of the company’s shares, worth $2.58M. The average tenure of the management team and the board of directors is 3.5 years and 6.8 years respectively.

Key information

Will Febbo

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage16.1%
CEO tenure8.8yrs
CEO ownership2.9%
Management average tenure3.5yrs
Board average tenure6.8yrs

Recent management updates

Recent updates

Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost

Dec 15
Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost

Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?

Nov 16
Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?

OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt

Jul 30
OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt

OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Jan 09
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

Aug 24
Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Aug 16
OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?

May 31
Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?

OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio

Oct 12

Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?

Sep 23
Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?

OptimizeRx extends reach with Cooler Screens Partnership

Jul 26

OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability

Jun 27

The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business

Nov 16
The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business

Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All

Aug 13
Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All

A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Jul 15
A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation

Jun 24
Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation

CEO Compensation Analysis

How has Will Febbo's remuneration changed compared to OptimizeRx's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$24m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$3mUS$450k

-US$18m

Sep 30 2023n/an/a

-US$14m

Jun 30 2023n/an/a

-US$14m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$694kUS$450k

-US$11m

Sep 30 2022n/an/a

-US$10m

Jun 30 2022n/an/a

-US$7m

Mar 31 2022n/an/a

-US$3m

Dec 31 2021US$15mUS$410k

US$378k

Sep 30 2021n/an/a

US$1m

Jun 30 2021n/an/a

US$789k

Mar 31 2021n/an/a

-US$641k

Dec 31 2020US$1mUS$350k

-US$2m

Sep 30 2020n/an/a

-US$6m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$834kUS$300k

-US$3m

Sep 30 2019n/an/a

-US$1m

Jun 30 2019n/an/a

US$548k

Mar 31 2019n/an/a

US$422k

Dec 31 2018US$923kUS$275k

US$226k

Sep 30 2018n/an/a

US$99k

Jun 30 2018n/an/a

-US$769k

Mar 31 2018n/an/a

-US$1m

Dec 31 2017US$422kUS$250k

-US$2m

Compensation vs Market: Will's total compensation ($USD2.79M) is above average for companies of similar size in the US market ($USD654.40K).

Compensation vs Earnings: Will's compensation has increased whilst the company is unprofitable.

CEO

Will Febbo (55 yo)

8.8yrs

Tenure

US$2,789,528

Compensation

Mr. William J. Febbo, also known as Will, is a Director at LifeMD, Inc. since June 2023. He served as an Independent Director at Augmedix, Inc. since March 28, 2022 until October 02, 2024. He served as an...

Leadership Team

NamePositionTenureCompensationOwnership
William Febbo
CEO & Director8.8yrsUS$2.79m2.86%
$ 2.6m
Stephen Silvestro
President1.9yrsUS$970.36k0.42%
$ 377.5k
Edward Stelmakh
CFO & COO3.2yrsUS$929.73k0.14%
$ 129.0k
Andrew D'Silva
Senior Vice President of Corporate Finance3.3yrsno datano data
Marion Odence-Ford
General Counsel & Chief Compliance Officer3.8yrsUS$2.51m0.11%
$ 99.1k
Maira Alejandra
Media Relations Managerno datano datano data
Sheryl Kearney
Human Resources Manager5yrsno datano data
Terence Hamilton
Senior Vice President of Pharma4.8yrsUS$511.63kno data
Doug Besch
Chief Product Officer2.2yrsno data0.034%
$ 30.4k
Theresa Greco
Chief Commercial Officer1.2yrsno data0.12%
$ 112.9k
Brian McCarthy
Chief Revenue Officerno datano datano data
Heather Favazza
Controller6.2yrsno datano data

3.5yrs

Average Tenure

56.5yo

Average Age

Experienced Management: OPRX's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
William Febbo
CEO & Director8.6yrsUS$2.79m2.86%
$ 2.6m
Patrick Spangler
Independent Director6.8yrsUS$215.01k0.17%
$ 158.0k
Catherine Klema
Independent Directorless than a yearno datano data
Gregory Wasson
Independent Director4.4yrsUS$195.01k0.18%
$ 167.1k
Ellen Vos
Independent Chairperson of the Board9.3yrsUS$208.01k0.27%
$ 243.0k
Jack Pinney
Head of Medical Advisory Board6.8yrsUS$112.91kno data
James Lang
Independent Director7.9yrsUS$204.01k0.30%
$ 268.9k

6.8yrs

Average Tenure

66yo

Average Age

Experienced Board: OPRX's board of directors are considered experienced (6.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 21:35
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OptimizeRx Corporation is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle BauserB. Riley Securities, Inc.
Constantine DavidesJMP Securities
Eric MartinuzziLake Street Capital Markets, LLC